• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

New Immunooncology Drug from Incyte Raises Immense Interest at ASCO

Article

Excitement at ASCO 2014 on Incyte's new immunoonoclogy drug candidate, INCB024360 ('360),in melanoma, despite a small 'n'.

We just got our first look at the clinical activity of

(INCY)

immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with

(BMY)

Yervoy in melanoma patients

Incyte'sBristol-Myers Squibb's

Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response

of 50%. A third patient reported stable disease so the disease control rate was 75%. The

.

Story:

rateIncyte press release and poster can be found herehttp://bit.ly/1pP7ZeT

Source: The Street

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.